[Pro3]-GIP (Mouse)
| Code | Size | Price |
|---|
| TAR-TP2020-5mg | 5mg | £401.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insulin sensitivity, and glucose response to feeding in ob/ob mice.
CAS:
TP2020
Formula:
C225H342N62O64S
Molecular Weight:
4971.62
Purity:
0.98
SMILES:
0
References
Gault et al (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent Insotropic polypeptide. Biochem.Biophys.Res.Commun. 290 1420 PMID:
Irwin et al (2007) Early administration of the glucose-dependent Insotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 50 1532 PMID: